119140 | Adenosine Receptor Agonist, NECA - CAS 35920-39-9 - Calbiochem

119140
Price could not be retrieved
Minimum Quantity needs to be mulitiple of
Upon Order Completion More Information
You Saved ()
 
Request Pricing
Limited AvailabilityLimited Availability
Stocked 
Discontinued
Limited Quantities Available
Available
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      View Pricing & Availability
      Click To Print This Page

      Overview

      Replacement Information

      Pricing & Availability

      Catalog NumberAvailability Packaging Qty/Pack Price Quantity
      119140-10MG
      Retrieving availability...
      Limited AvailabilityLimited Availability
      Stocked 
      Discontinued
      Limited Quantities Available
      Available
        Remaining : Will advise
          Remaining : Will advise
          Will advise
          Contact Customer Service

          Glass bottle 10 mg
          Retrieving price...
          Price could not be retrieved
          Minimum Quantity needs to be mulitiple of
          Upon Order Completion More Information
          You Saved ()
           
          Request Pricing
          Description
          OverviewA cell-permeable adenosine analog that acts a potent non-selective agonist of adenosine receptors (Ki = 14 nM, 20 nM, 2.4 µM and 6.2 nM for A1, A2A, A2B, A3, respectively). Increases intracellular cAMP production (EC50 = 3.1 µM in A2B expressing CHO cells). Shown to increase glucagon release in a dose-dependent manner and inhibit insulin release at low concentrations. Although at higher concentration some insulin release is observed. Also, displays a wide range adenosine-dependent effects, such as blocking platelet aggregation and inhibiting DNA synthesis. When administered at reperfusion, it is shown reduce infarction and block the formation of the mitochondrial permeability transition pore by activating p70S6 kinase.
          Catalogue Number119140
          Brand Family Calbiochem®
          Synonyms(2S,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-N-ethyl-3,4-dihydroxytetrahydrofuran-2-carboxamide
          References
          ReferencesForster, K., et al. 2006. Basic Res. Cardiol. 101, 319.
          de Zwart, M., et al. 1998. Nucleosides Nucleotides. 17, 969.
          Phillis, J. et al. 1986, Pharm. Biochem. Behavior.24, 263
          Durcan, M. J., et al. 1989. Pharmacol Biochem Behav. 32, 487.
          Bacher, S., et al. 1982. Naunyn Schmiedebergs Arch Pharmacol. 329, 67.
          Cusack, N., et al. 1981. Br J Pharm.72, 443.
          Londos, C., et al. 1980. Proc Natl Acad Sci.77, 2551.
          Product Information
          CAS number35920-39-9
          FormWhite solid
          Hill FormulaC₁₂H₁₆N₆O₄
          Chemical formulaC₁₂H₁₆N₆O₄
          ReversibleY
          Structure formula ImageStructure formula Image
          Applications
          Biological Information
          Primary Target K<sub>i</sub>14 nM
          Purity≥99% by HPLC
          Physicochemical Information
          Dimensions
          Materials Information
          Toxicological Information
          Safety Information according to GHS
          Safety Information
          Product Usage Statements
          Storage and Shipping Information
          Ship Code Shipped at Ambient Temperature or with Blue Ice or with Dry Ice
          Toxicity Standard Handling
          Storage +2°C to +8°C
          Protect from Light Protect from light
          Do not freeze Ok to freeze
          Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
          Packaging Information
          Packaged under inert gas Packaged under inert gas
          Transport Information
          Supplemental Information
          Specifications

          Documentation

          SDS

          Title

          Safety Data Sheet (SDS) 

          Certificates of Analysis

          TitleLot Number
          119140

          References

          Reference overview
          Forster, K., et al. 2006. Basic Res. Cardiol. 101, 319.
          de Zwart, M., et al. 1998. Nucleosides Nucleotides. 17, 969.
          Phillis, J. et al. 1986, Pharm. Biochem. Behavior.24, 263
          Durcan, M. J., et al. 1989. Pharmacol Biochem Behav. 32, 487.
          Bacher, S., et al. 1982. Naunyn Schmiedebergs Arch Pharmacol. 329, 67.
          Cusack, N., et al. 1981. Br J Pharm.72, 443.
          Londos, C., et al. 1980. Proc Natl Acad Sci.77, 2551.
          Data Sheet

          Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

          Revision28-March-2013 JSW
          Synonyms(2S,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-N-ethyl-3,4-dihydroxytetrahydrofuran-2-carboxamide
          DescriptionA cell-permeable adenosine analog that acts a potent non-selective agonist of adenosine receptors (Ki = 14 nM, 20 nM, 2.4 µM and 6.2 nM for A1, A2A, A2B, A3, respectively). Increases intracellular cAMP production (EC50 = 3.1 µM in A2B expressing CHO cells). Shown to increase glucagon release in a dose-dependent manner and inhibit insulin release at low concentrations. Although at higher concentration some insulin release is observed. Also, displays a wide range adenosine-dependent effects, such as blocking platelet aggregation and inhibiting DNA synthesis. When administered at reperfusion, it is shown reduce infarction and block the formation of the mitochondrial permeability transition pore by activating p70S6 kinase.
          FormWhite solid
          Intert gas (Yes/No) Packaged under inert gas
          CAS number35920-39-9
          Chemical formulaC₁₂H₁₆N₆O₄
          Structure formulaStructure formula
          Purity≥99% by HPLC
          SolubilityDMSO (50 mM)
          Storage +2°C to +8°C
          Protect from light
          Do Not Freeze Ok to freeze
          Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
          Toxicity Standard Handling
          ReferencesForster, K., et al. 2006. Basic Res. Cardiol. 101, 319.
          de Zwart, M., et al. 1998. Nucleosides Nucleotides. 17, 969.
          Phillis, J. et al. 1986, Pharm. Biochem. Behavior.24, 263
          Durcan, M. J., et al. 1989. Pharmacol Biochem Behav. 32, 487.
          Bacher, S., et al. 1982. Naunyn Schmiedebergs Arch Pharmacol. 329, 67.
          Cusack, N., et al. 1981. Br J Pharm.72, 443.
          Londos, C., et al. 1980. Proc Natl Acad Sci.77, 2551.